Wall Street speculation that a pending ex-U.S. partnership "could lead into something greater or bigger" helped bump shares of Celator Pharmaceuticals Inc., but CEO Scott Jackson told BioWorld Today the promise of more color than expected on Vyxeos at next month's American Society of Clinical Oncology meeting may have helped, too.